442 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am
in research and development expenses was primarily due to costs related to the execution of the SEISMiC Extension trial of istaroxime for the treatment … weighted average common shares outstanding for the comparable period in 2022.
Select 2023 Year-End Financial Results
Research and development expenses
8-K
EX-2.1
WINT
Windtree Therapeutics Inc
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
, proprietary or confidential information (whether business, financial, commercial, medical, research and development, human resources, audit-related … Parties who could derive economic value from its use or disclosure, including confidential research and development information, Intellectual Property
8-K
EX-99.1
rz7707j8kvxkz35ezxke
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
424B5
q9ugjdpihh5 rcvq
9 Nov 23
Prospectus supplement for primary offering
4:11pm
8-K
EX-99.1
5vcko 4gd
7 Aug 23
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
4:02pm
8-K
EX-99.1
d73ay4n2e
15 May 23
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
4:24pm
424B4
b4fnl9l8e9 b6kee
20 Apr 23
Prospectus supplement with pricing info
6:03pm
8-K
EX-99.1
6hhq1w06bl5aj8tr20
3 Apr 23
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates
7:25am